This company has been acquired
FMTX Stock Overview
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Forma Therapeutics Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.01 |
| 52 Week High | US$20.68 |
| 52 Week Low | US$4.95 |
| Beta | -0.95 |
| 1 Month Change | 0.25% |
| 3 Month Change | 138.50% |
| 1 Year Change | 10.61% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -48.69% |
Recent News & Updates
We're Keeping An Eye On Forma Therapeutics Holdings' (NASDAQ:FMTX) Cash Burn Rate
Aug 30
Forma Therapeutics GAAP EPS of -$1.10 misses by $0.11
Aug 05Recent updates
We're Keeping An Eye On Forma Therapeutics Holdings' (NASDAQ:FMTX) Cash Burn Rate
Aug 30Forma Therapeutics GAAP EPS of -$1.10 misses by $0.11
Aug 05We're Hopeful That Forma Therapeutics Holdings (NASDAQ:FMTX) Will Use Its Cash Wisely
Mar 04We're Hopeful That Forma Therapeutics Holdings (NASDAQ:FMTX) Will Use Its Cash Wisely
Nov 20Here's Why We're Not Too Worried About Forma Therapeutics Holdings' (NASDAQ:FMTX) Cash Burn Situation
Aug 13We Think Forma Therapeutics Holdings (NASDAQ:FMTX) Needs To Drive Business Growth Carefully
Apr 18What Type Of Shareholders Own The Most Number of Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) Shares?
Jan 03Forma Therapeutics closes public offering priced at $45.25
Dec 16Forma Therapeutics prices equity offering at $45.25
Dec 11Forma Therapeutics' sickle cell treatment shows promising action at ASH presentation
Dec 08Forma Therapeutics EPS beats by $0.01
Nov 12Forma Therapeutics' sickle cell candidate an orphan drug in Europe
Nov 10Shareholder Returns
| FMTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.3% | -2.5% | -3.2% |
| 1Y | 10.6% | -3.7% | 19.3% |
Return vs Industry: FMTX exceeded the US Biotechs industry which returned -22.4% over the past year.
Return vs Market: FMTX exceeded the US Market which returned -25.7% over the past year.
Price Volatility
| FMTX volatility | |
|---|---|
| FMTX Average Weekly Movement | 15.9% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: FMTX's share price has been volatile over the past 3 months.
Volatility Over Time: FMTX's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 189 | Frank Lee | www.formatherapeutics.com |
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver.
Forma Therapeutics Holdings, Inc. Fundamentals Summary
| FMTX fundamental statistics | |
|---|---|
| Market cap | US$957.72m |
| Earnings (TTM) | -US$190.15m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.0x
P/E RatioIs FMTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FMTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$127.07m |
| Gross Profit | -US$127.06m |
| Other Expenses | US$63.09m |
| Earnings | -US$190.15m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.97 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did FMTX perform over the long term?
See historical performance and comparison